Lack of effect of ketoconazole-mediated CYP3A inhibition on sorafenib clinical pharmacokinetics.

Cancer chemotherapy and pharmacology

Volumn 57, Issue 5, 2006, Pages 685-692

  Lathia, Chetan ^a   Lettieri, John ^a   Cihon, Frank ^a   Gallentine, Martha ^a   Radtke, Martin ^a   Sundaresan, Pavur ^a  

^a BAYER CORPORATION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIFUNGAL AGENT; BENZENESULFONIC ACID DERIVATIVE; CYP3A PROTEIN, HUMAN; CYP3A4 PROTEIN, HUMAN; CYTOCHROME P450; ENZYME INHIBITOR; KETOCONAZOLE; PYRIDINE DERIVATIVE; SORAFENIB;

ADULT; ARTICLE; BLOOD; CROSSOVER PROCEDURE; DRUG ANTAGONISM; HUMAN; MALE; MIDDLE AGED;

ADULT; ANTIFUNGAL AGENTS; BENZENESULFONATES; CROSS-OVER STUDIES; CYTOCHROME P-450 ENZYME SYSTEM; ENZYME INHIBITORS; HUMANS; KETOCONAZOLE; MALE; MIDDLE AGED; PYRIDINES;

EID: 33645648696     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00280-005-0068-6     Document Type: Article

References (0)